What if I lose too much weight on tirzepatide or semaglutide?
A prescriber can consider a lower dose of tirzepatide (Mounjaro, Zepbound) or semaglutide (Wegovy), though labels differ by country. The US Zepbound and Wegovy labels say the maintenance dose is chosen by response and tolerability, injected once weekly. Rapid weight loss can raise gallstone risk, and the NHS advises seeing a GP about sudden or unexplained weight loss.
Can the dose be lowered?
The US Zepbound and Wegovy labels both say the maintenance dose is chosen with treatment response and tolerability in mind, so a prescriber can choose a lower maintenance dose.12
For Zepbound, the maintenance doses are 5 mg, 10 mg or 15 mg once weekly. The 2.5 mg dose is only for starting. If a maintenance dose is not tolerated, the label says a lower one can be considered.1 For Wegovy injection, the weight maintenance dose is 1.7 mg or 2.4 mg once weekly, with an optional step up to 7.2 mg.2 Labels outside the US word this differently (see In your country below).
Both labels keep a once-weekly schedule. The Zepbound label says a missed dose can be taken within 4 days. After that, skip it and inject on the usual day.1 The NHS says not to stop tirzepatide suddenly, and that a doctor may suggest lowering the dose gradually.3
In trials, stopping brought much of the weight back. In SURMOUNT-4, the weight of people switched to placebo rose by an average of 14% over the next year. People who stayed on tirzepatide lost a further 5.5%.7 In the STEP 1 extension, people regained two-thirds of the weight they had lost within a year of stopping semaglutide.6 Our guide to stopping (US edition) covers what follows.
What are the risks of losing weight fast?
The US Wegovy label says substantial or rapid weight loss can raise the risk of gallstones, and both US labels report more low blood pressure than placebo.21
The Wegovy label adds that gallbladder disease was still more common than on placebo after allowing for the amount of weight lost.2 The Zepbound label links gallbladder events to weight loss. Gallbladder inflammation (cholecystitis) affected 0.7% of people on Zepbound, against 0.2% on placebo.1
Low blood pressure, including on standing, affected 1.6% of people on Zepbound against 0.1% on placebo. It was more common in people also taking blood pressure medicines (2.2% against 1.2%), and it also came with gut side effects and dehydration.1 On Wegovy, 1.3% had low blood pressure against 0.4%, and 0.8% fainted against 0.2%.2
Both labels say these medicines cause more fat loss than loss of lean mass (muscle and other non-fat tissue), so some lean mass is lost too.12
When does weight loss need checking?
The NHS says to see a GP if you keep losing weight without changing what you eat or how active you are, and soon if other symptoms come with it.4
Causes the NHS lists include an overactive thyroid, depression, anxiety and eating disorders, gut conditions such as coeliac disease, and a poor appetite.4 Weight loss on one of these medicines can still have another cause.
The WHO classes an adult with a body mass index (BMI) below 18.5 as underweight.16
The NHS says being underweight can lead to a weak immune system, broken bones and missing vitamins and minerals. It also suggests speaking to a GP if you use control of food to cope with emotions.5
What do people on GLP-1 medicines report about losing too much weight?
From public patient forums: 34 Reddit threads in r/Zepbound, r/Mounjaro, r/mounjarouk, r/MounjaroMaintenance, r/Ozempic and r/WegovyWeightLoss, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Matches the label Many say their appetite almost disappeared, and their weight kept falling past their goal. Both US labels say these medicines lower how much you eat, probably by acting on appetite. They do not speak to weight falling past a goal.12
- Matches the label Several describe dizziness on standing, tiredness, feeling cold or weakness. The US labels speak only to the dizziness. They report low blood pressure, including on standing, more often than on placebo.12
- Not studied Several say they are now underweight or were told by a doctor they are too light. The NHS says being underweight in general can weaken the immune system and lead to broken bones.5
Advice people share
- Matches the label Many advise asking the prescriber about stepping the dose down rather than stopping suddenly. The US labels choose the maintenance dose by response and tolerability, and the NHS says not to stop tirzepatide suddenly.123
- Matches the NHS Many suggest blood tests to rule out other causes when loss is unexplained or comes with symptoms. The NHS lists causes such as an overactive thyroid.4
- Matches the trial Several warn that stopping outright tends to bring weight back. In SURMOUNT-4 and the STEP 1 extension, much of the lost weight returned within a year of stopping.67
- Label says otherwise Many posts describe stretching the gap between injections or making partial or home-made doses. The US labels set fixed doses injected once weekly; Zepbound's 4-day window is only for a missed dose, not a planned gap.12
In your country
The once-weekly schedule is the same in every label we read. Labels differ on whether and how long a maintenance dose can be lowered, and we could not open labels for India, Saudi Arabia or the UAE.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: The Australian Mounjaro label says 5 mg, 10 mg and 15 mg are the doses to stay on, and that 2.5 mg, 7.5 mg and 12.5 mg are not maintenance doses.14 The Australian Wegovy label allows 1.7 mg for maintenance if 2.4 mg is not tolerated, going back to 2.4 mg if tolerated.15
Emergency number: 000
What are the side effects of GLP-1 medicines like Ozempic and Mounjaro? (Australia guide)
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The Canadian Wegovy monograph allows dropping from 2.4 mg to 1.7 mg for at most 4 weeks, then going back up to 2.4 mg.13 For tirzepatide, this page relies on the US label above.
Emergency number: 911
What are the side effects of GLP-1 medicines like Ozempic and Mounjaro? (Canada guide)
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The EU Mounjaro label lists 5 mg, 10 mg and 15 mg as maintenance doses, with no line on lowering a maintenance dose.10 The EU Wegovy label names 2.4 mg as the maintenance dose. It allows going back to the previous dose only until significant gut symptoms improve.9
Emergency number: 15 or 112
Side effects of GLP-1 medicines: the France guide (in French)
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The EU Mounjaro label lists 5 mg, 10 mg and 15 mg as maintenance doses, with no line on lowering a maintenance dose.10 The EU Wegovy label names 2.4 mg as the maintenance dose, and says 7.2 mg should go back to 2.4 mg if it brings no further weight benefit. It allows going back to the previous dose until significant gut symptoms improve.9
Emergency number: 112
Side effects of GLP-1 medicines: the Germany guide (in German)
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We could not find an Indian label to open, so this page relies on the US labels and EU product information cited above.
Emergency number: 112
What are the side effects of GLP-1 medicines like Ozempic and Mounjaro? (India guide)
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We could not find a Saudi label to open, so this page relies on the US labels and EU product information cited above.
Emergency number: 997 or 911
Side effects of GLP-1 medicines: the Saudi Arabia guide (in Arabic)
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not find a UAE label to open, so this page relies on the US labels and EU product information cited above.
Emergency number: 998 for an ambulance, or 999
What are the side effects of GLP-1 medicines like Ozempic and Mounjaro? (UAE guide)
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK Mounjaro label lists 5 mg, 10 mg and 15 mg as maintenance doses, with no line on lowering a maintenance dose.11 The UK Wegovy label names 2.4 mg as the maintenance dose. It allows going back to the previous dose until significant gut symptoms improve.12
Emergency number: 999
What are the side effects of GLP-1 medicines like Ozempic and Mounjaro? (UK guide)
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
What are the side effects of GLP-1 medicines like Ozempic, Wegovy and Zepbound? (US guide)
Contact your prescriber if you have signs of gallbladder trouble, and see a doctor as soon as possible if weight loss comes with other symptoms.124
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information, Eli Lilly. pi.lilly.com
- US Wegovy (semaglutide) prescribing information, Novo Nordisk. novo-pi.com
- NHS. Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. nhs.uk
- NHS. Unintentional weight loss. nhs.uk
- NHS. Advice for underweight adults. nhs.uk
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022. doi.org/10.1111/dom.14725
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. doi.org/10.1001/jama.2023.24945
- American College of Emergency Physicians. Know When to Go. emergencyphysicians.org
- EU Wegovy (semaglutide) Summary of Product Characteristics, European Medicines Agency. ema.europa.eu
- EU Mounjaro (tirzepatide) Summary of Product Characteristics, European Medicines Agency. ema.europa.eu
- UK Mounjaro KwikPen (tirzepatide) Summary of Product Characteristics, emc. medicines.org.uk
- UK Wegovy FlexTouch (semaglutide) Summary of Product Characteristics, emc. medicines.org.uk
- Canadian Wegovy (semaglutide) Product Monograph, Health Canada. pdf.hres.ca
- Australian Mounjaro (tirzepatide) Product Information, version A14.0, October 2026. medsinfo.com.au
- Australian Wegovy (semaglutide) Product Information. medsinfo.com.au
- WHO Regional Office for Europe. Nutrition for a healthy life: WHO recommendations. who.int
Last checked Nov 16, 2026 · Next review due Nov 16, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 16, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write